Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 4 of 4 citing Stewart: Half dose verteporfin PDT for central serous chorioretinopathy. (0.08 sec) 

Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year …

- sommerfeld-net.de [PDF] 
WM Chan, TYY LAI, RYK LAI, EWH TANG, … - Retina, 2008 - journals.lww.com
Central serous chorioretinopathy (CSC) is character- ized by the development of
serous neurosensory retinal detachment at the posterior pole.1 In the majority
of patients, CSC is self-limiting and patients usually have
Cited by 12 - Related articles - BL Direct - All 3 versions

Verteporfin photodynamic therapy in the age of antiangiogenic therapy


IA Barbazetto, BS Takahashi - Expert Review of Ophthalmology, 2008 - ingentaconnect.com
Photodynamic therapy with verteporfin was the first approved pharmacological
treatment for choroidal neovascularization in patients with age-related macular
degeneration, pathologic myopia and ocular histoplasmosis syndrome. With ...
Related articles - All 3 versions

Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous …


M Reibaldi, N Cardascia, A Longo, C Furino, … - American Journal of Ophthalmology, 2009 - Elsevier
Mean logarithm of the minimal angle of resolution best-corrected visual acuity
improved significantly at all time points (P < .01), in the standard-fluence
group from 0.43 to 0.24 at 12 months and in the low-fluence-group from 0.46 ...

[CITATION] . Retina-Emily C. Fletcher, MBChB, MRCOphth, NH Victor Chong, MPhil, DO, FRCS


F FRCOphth, DJ Shetlar
Related articles


 


Go to Google Home - About Google - About Google Scholar

©2009 Google